# Spray Venture Partners

> Spray Venture Partners is a VC fund backing Health Care and Medical Device. See 20 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Newton, United States
- Total investments: 20
- Last investment: Oct 2013
- Lead investor: 0%
- Last updated: Aug 2026
- Website: http://www.spraypartners.com

Spray Venture Partners is a VC fund in Newton focused on Health Care and Medical Device. Spray Venture Partners focuses exclusively on contributing capital and expertise to emerging healthcare technology companies. They work closely with clinical and technical founders to create companies that develop, market and deploy innovative technologies to meet major unmet healthcare needs.

## Contacts

5 contacts available for Spray Venture Partners. Shizune tracks 3 team members at Spray Venture Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/spray-venture-partners?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 9 | 45% |
| Medical Device | 9 | 45% |
| Medical | 5 | 25% |
| Biotechnology | 5 | 25% |
| Manufacturing | 4 | 20% |

14 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 6 | 30% |
| Series B | 5 | 25% |
| Funding Round | 5 | 25% |
| Series D | 2 | 10% |
| Series A | 1 | 5% |

6 stages tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Daniel Cole | General Partner | 16 | https://shizune.co/investors/profile/daniel-cole-2 |
| Kevin Connors | Founder & General Partner | 6 | https://shizune.co/investors/profile/kevin-connors |
| Lisa Dunlea | Team Member | 0 | https://shizune.co/investors/profile/lisa-dunlea |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Conventus Orthopaedics | Conventus Orthopaedics provides a range of orthopedic and sports medicine services. The physicians specialize in orthopedic surgery, reconstructive surgery, spine surgery, joint replacement, sports medicine, physical therapy, and operative care of fractures, arthritis, strains, sprains, and sports-related injuries. Conventus was formed by a team ofmedical professionals with the sole purpose of creating less invasive ways to treat challenging periarticular fractures. By leveraging advanced nitinol technology, the Conventus team has developed a platform technology that provides robust fixation and creates reliable repairs.The company was incorporated in 2009 and is based in Maple Grove, Minnesota. |  |  | Oct 03, 2013 |  |
| Tryton Medical | Tryton Medical, Inc. develops stent systems for the treatment of cardiovascular diseases in the United States, Austria, Belgium, Denmark, Ireland, Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, and the United Kingdom. It offers the Tryton Side Branch Stent System, which offers a strategy for treating atherosclerotic lesions in theside branch at the site of a bifurcation. The company was founded in 2003 and is based in Durham, North Carolina. | $24M |  | Jan 07, 2013 |  |
| Direct Flow Medical | Direct Flow Medical is a medical device company developing a percutaneous aortic tissue valve prosthesis to provide patients requiring treatment of cardiac valve insufficiency with a safe and effective percutaneous option. Approximately 1.2 million people over the age of 65 have calcified aortic valves, yet only an estimated 150,000 are surgicallytreated each year. | $284K |  | Apr 01, 2012 |  |
| PneumRx | PneumRx, Inc., a start-up medical device company, develops minimally invasive treatments for emphysema patients. The company develops RePneu Lung Volume Reduction Coil, an investigational device for treating emphysema patients. PneumRx, Inc. was founded in 2004 and is based in Mountain View, California. | $33M |  | Jan 04, 2011 |  |
| Tryton Medical | Tryton Medical, Inc. develops stent systems for the treatment of cardiovascular diseases in the United States, Austria, Belgium, Denmark, Ireland, Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, and the United Kingdom. It offers the Tryton Side Branch Stent System, which offers a strategy for treating atherosclerotic lesions in theside branch at the site of a bifurcation. The company was founded in 2003 and is based in Durham, North Carolina. | $20M | Series D | Sep 14, 2010 |  |
| TearScience | Headquartered in Morrisville, North Carolina, TearScience has pioneered devices that provide significant clinical identification and treatment of evaporative dry eye. Of the 100 million plus of dry eye sufferers worldwide, the leading cause (86percent) is evaporative dry eye, which is caused by Meibomian Gland Dysfunction (MGD) and a lipiddeficiency of the eye’s natural tear film. The Tear Film and Ocular Surface Society (TFOS) workshop, involving two years of work by 50 leading experts from around the world, concluded that MGD is an under-estimated condition and is very likely the most frequent cause of dry eye disease. Common symptoms of the disease include eye irritation, dryness, redness, tiredness, and visual disturbances. TearScience’s integrated, in-office system enables eye care professionals to effectively address a root cause of evaporative dry eye. |  | Series C | May 06, 2010 |  |
| Barricaid | Intrinsic Therapeutics is a medical device company that develops therapies for treating disc herniations in the spine for discectomy patients. It offers Barricaid anular prosthesis that allows the direct reconstruction of weakened and ruptured annulus and soft tissues of the spine. The company also offers spinal implants to treat the causes ofsciatica and low back pain. It serves surgeons and patients. The company was formerly known as Intrinsic Orthopedics and changed its name to Intrinsic Therapeutics in January 2003. Intrinsic Therapeutics was founded in 2000 and is based in Woburn, Massachusetts. | $18M |  | Feb 26, 2010 |  |
| Direct Flow Medical | Direct Flow Medical is a medical device company developing a percutaneous aortic tissue valve prosthesis to provide patients requiring treatment of cardiac valve insufficiency with a safe and effective percutaneous option. Approximately 1.2 million people over the age of 65 have calcified aortic valves, yet only an estimated 150,000 are surgicallytreated each year. | $40M | Series C | Oct 05, 2009 |  |
| Interlace Medical | Interlace Medical, Inc. is focused on designing and developing devices for the Interventional Gynecologist to perform office-based procedures to treat diseases and conditions traditionally requiring surgery in the operating room. | $20.5M | Series C | Jul 07, 2009 |  |
| Facet Solutions | Facet Solutions develops surgical devices for the treatment of degenerative spinal disorders. Facet Solutions was founded on 2003 and is based in Hopkinton, Massachusetts. | $4.1M | Debt Financing | Jun 12, 2009 |  |

10 of 20 investments shown.

## Co-investors
- [EDF Ventures](https://shizune.co/investors/profile/edf-ventures) — VC Fund, 4 deals together
- [Alta Partners](https://shizune.co/investors/profile/alta-partners) — VC Fund, 3 deals together
- [Johnson & Johnson Development Corporation](https://shizune.co/investors/profile/johnson-johnson-development-corporation) — VC Fund, 3 deals together
- [New Leaf Venture Partners](https://shizune.co/investors/profile/new-leaf-venture-partners) — VC Fund, 3 deals together
- [Sprout Group](https://shizune.co/investors/profile/the-sprout-group) — VC Fund, 3 deals together
- [VantagePoint Capital Partners](https://shizune.co/investors/profile/vantagepoint-capital-partners) — VC Fund, 3 deals together

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Spray Venture Partners invest in?

Spray Venture Partners invests primarily in Health Care, Medical Device and Medical startups, most often at Series C and Series B stage. Most of the 20 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Spray Venture Partners?

Public channels for Spray Venture Partners include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Spray Venture Partners?

The team at Spray Venture Partners includes Daniel Cole (General Partner), Kevin Connors (Founder & General Partner) and Lisa Dunlea (Team Member). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co